Oncology cancer drugs market (therapeutic modalities, cancer types and geography) forecast 2013 2020

Global Oncology/Cancer Drugs Market (Therapeutic Modalities, Cancer Types and Geography) Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

Š ALLIED MARKET RESEARCH

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies would restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the market growth.

The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.

Get Full Access for the Report at: http://www.alliedmarketresearch.com/oncology-cancer-drugsmarket Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.

Key companies profiled in the report are Roche diagnostics, Novartis AG, Celgene Corporation, AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co. and GlaxoSmithKline. Companies operating in the cancer drugs market focus on several strategies such as collaboration, approval and acquisition.

KEY BENEFITS  

The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on The report helps in understanding the strategies adopted by various companies for gaining market share in the cancer drugs market Š ALLIED MARKET RESEARCH

   

The report provides comprehensive analysis of factors that drive and restrict the growth of the cancer drugs market Market conditions of cancer drugs market across all geographic regions are comprehensively analyzed Competitive intelligence (of leading manufacturers) helps in understanding the competitive scenario across the geographies SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies MARKET SEGMENTATION The cancer drugs market is segmented by the therapeutic modalities, cancer types and geography.

MARKET BY THERAPEUTIC MODALITIES

    

Chemotherapy Targeted Therapy Immunotherapy (Biologic Therapy) Hormonal Therapy Others MARKET BY CANCER TYPES

      

Blood Cancer Breast Cancer Gastrointestinal Cancer Prostate Cancer Respiratory/Lung Cancer Skin Cancer Other Cancers MARKET BY GEOGRAPHY





North America  United States  Canada  Mexico Europe  Germany © ALLIED MARKET RESEARCH

France  United Kingdom  Others Asia-Pacific  India  China  Japan  Australia  Others LAMEA  GCC (Gulf Corporation Council)  Others 





About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us: Cathy Viber 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States.

Direct: +1(503)505-6949 Toll Free: +1(855)711-1555 (U.S. & Canada) Fax: +1(855)550-5975 Email: query@alliedmarketresearch.com Web: http://www.alliedmarketresearch.com/

© ALLIED MARKET RESEARCH

© ALLIED MARKET RESEARCH

© ALLIED MARKET RESEARCH